All In Biotech

Drug Trial Radar · NCT04669808

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Localized Injection of STP705 in Adult Patients With Basal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Dec 28, 2020

Primary completion

Feb 9, 2023

Study completion Feb 9, 2023

Sponsor

Lead sponsor
SirnaomicsIndustry
Sponsor type
Industry
Collaborators
Amarex Clinical Research
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC). Goals: * To determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma. * Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.

Conditions

  • Basal Cell Carcinoma

Interventions

  • STP705Drug

    Dry powder for intra-and peri-lesional injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at the End of Treatment (EOT)Time frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Clinical and Cosmetic Research

    Aventura, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.